# LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Source: https://onco.cc/trials/nct06216301/  
OnCo record `nct06216301` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by NovoCure GmbH, now recruiting.

## Summary

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC is a phase 3 interventional study registered as NCT06216301 by NovoCure GmbH, with 734 participants planned, started 2024-07-31 and due to reach its primary completion in 2028-10. Interventions recorded: NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy. Conditions listed: Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06216301
- Phase: 3
- Setting: LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
- Sponsor: NovoCure GmbH
- Enrolled: 734

## Sources

- ClinicalTrials.gov NCT06216301: https://clinicaltrials.gov/study/NCT06216301

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/)
- companies: [Novocure](https://onco.cc/companies/novocure/)

---
JSON: https://onco.cc/api/v1/entities/nct06216301.json